With the acceleration of population aging, multimorbidity has become a critical challenge urgently requiring solutions in the global healthcare field. As a core tool for standardizing clinical practices and improving medical quality, clinical practice guidelines have demonstrated significant value in clinical settings. The number of current multimorbidity guidelines is relatively limited, and their development, evaluation, and implementation still face many challenges. These barriers include insufficient direct evidence, obstacles to multidisciplinary collaboration, and inadequate clinical applicability. The rapid development of digital health technologies provides a comprehensive solution for optimizing multimorbidity guidelines. this study explores how digital health technologies—such as big data, artificial intelligence, and digital platforms—can assist researchers in optimizing the entire process from the development to implementation of multimorbidity guidelines, providing new pathways to overcome bottlenecks in multimorbidity management and enhance the practical value of guidelines.

1.The Academy of Medical Sciences. Multimorbidity: a priority for global health research[R/OL]. (2018) [2024-12-24]. https://acmedsci.ac.uk/file-download/82222577

2.Guthrie B, Thompson A, Dumbreck S, et al. Better guidelines for better care: accounting for multimorbidity in clinical guidelines - structured examination of exemplar guidelines and health economic modelling[M]. Southampton (UK): NIHR Journals Library, 2017.

3.Dugravot A, Fayosse A, Dumurgier J, et al. Social inequalities in multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II cohort study[J]. Lancet Public Health, 2020, 5(1): e42-e50.

4.Skou ST, Mair FS, Fortin M, et al. Multimorbidity[J]. Nat Rev Dis Primers, 2022, 8(1): 48.

5.Wei MY, Mukamal KJ. Multimorbidity, mortality, and long-term physical functioning in 3 prospective cohorts of community-dwelling adults[J]. Am J Epidemiol, 2018, 187(1): 103-112.

6.中国肌少症诊断与治疗指南(2024版)编写组. 中国肌少症诊断与治疗指南(2024版)[J]. 中华医学杂志, 2025, 105(3): 181-203. [Guideline for diagnosis and treatment of sarcopenia in China (2024 edition)[J]. National Medical Journal of China, 2025, 105(3): 181-203.]

7.Prados-Torres A, Calderón-Larrañaga A, Hancco-Saavedra J, et al. Multimorbidity patterns: a systematic review[J]. J Clin Epidemiol, 2014, 67(3): 254-266.

8.Li FR, Wang S, Li X, et al. Multimorbidity and mortality among older patients with coronary heart disease in Shenzhen, China[J]. J Geriatr Cardiol, 2024, 21(1): 81-89.

9.Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition--multimorbidity[J]. JAMA, 2012, 307(23): 2493-2494.

10.Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services[J]. J Am Coll Cardiol, 2014, 64(17): 1851-1856.

11.Wang Z, Zhu D, Zhang H, et al. Recommendations and quality of multimorbidity guidelines: a systematic review[J]. Ageing Res Rev, 2024, 102: 102559.

12.World Health Organization. Global strategy on digital health 2020-2025[M]. Geneva: World Health Organization, 2021.

13.Adan M, Gillies C, Tyrer F, et al. The multimorbidity epidemic: challenges for real-world research[J]. Prim Health Care Res Dev, 2020, 21: e6.

14.王行环, 王强, 靳英辉. 临床实践指南的制订、评价与实施 [M]. 北京: 人民卫生出版社, 2022. [Wang XH, Wang Q, Jin YH. Development, Assessment and Implementation of Clinical Practice Guidelines[M]. Beijing: People's Medical Publishing House, 2022.]

15.Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions[J]. N Engl J Med, 2004, 351(27): 2870-2874.

16.Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance[J]. JAMA, 2005, 294(6): 716-724.

17.Mutasingwa DR, Ge H, Upshur REG. How applicable are clinical practice guidelines to elderly patients with comorbidities?[J]. Can Fam Physician, 2011, 57(7): e253-e262.

18.American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Patient-centered care for older adults with multiple chronic conditions: a stepwise approach from the American Geriatrics Society[J]. J Am Geriatr Soc, 2012, 60(10): 1957-1968.

19.Farmer C, Fenu E, O'Flynn N, et al. Clinical assessment and management of multimorbidity: summary of NICE guidance[J]. BMJ, 2016, 354: i4843.

20.国家重点研发项目(2018YFC2002400)课题组. 高龄老年共病患者多重用药安全性管理专家共识[J]. 中华保健医学杂志, 2021, 23(5): 548-554. [Research Group of National Key Research and Development Program of China (2018YFC2002400). Expert consensus on the safety management of polypharmacy in elderly patients with multimorbidity[J]. Chinese Journal of Health Care and Medicine, 2021, 23(5): 548-554.]

21.朱鸣雷, 刘晓红, 董碧蓉, 等. 老年共病管理中国专家共识(2023) [J]. 中国临床保健杂志, 2023, 26(5): 577-584. [Zhu ML, Liu XH, Dong BR, et al. Chinese expert consensus on management of elderly patients with multimorbidity (2023)[J]. Chinese Journal of Clinical Healthcare, 2023, 26(5): 577-584.]

22.陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版)[J]. 中华医学杂志, 2022, 102(10): 697-703.[Chen YL, Yang KH, Wang XQ, et al. Guidelines for the development/revision of clinical diagnosis and treatment guidelines in China (2022 Edition)[J]. Chinese Medical Journal, 2022, 102(10): 697-703.]

23.Muth C, Blom JW, Smith SM, et al. Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensus[J]. J Intern Med, 2019, 285(3): 272-288.

24.Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition--multimorbidity[J]. JAMA, 2012, 307(23): 2493-2494.

25.Wilson KC, Gould MK, Krishnan JA, et al. An official American thoracic society workshop report. a framework for addressing multimorbidity in clinical practice guidelines for pulmonary disease, critical illness, and sleep disorders[J]. Ann Am Thoracic Soc, 2016, 13(3): S12-S21.

26.Uhlig K, Leff B, Kent DM, et al. A framework for crafting clinical practice guidelines that are relevant to the care and management of people with multimorbidity[J]. J Gen Intern Med, 2014, 29(4): 670-679.

27.Moayyedi P, Marsiglio M, Andrews CN, et al. Patient engagement and multidisciplinary involvement has an impact on clinical guideline development and decisions: a comparison of two irritable bowel syndrome guidelines using the same data[J]. J Can Assoc Gastroenterol, 2019, 2(1): 30-36.

28.Oosterhuis WP, Bruns DE, Watine J, et al. Evidence-based guidelines in laboratory medicine: principles and methods[J]. Clin Chem, 2004, 50(5): 806-818.

29.王子君, 史乾灵, 宫恩莹, 等. 共病指南: 现状、挑战与机遇 [J]. 中国循证医学杂志, 2024, 24(6): 621-625. [Wang ZJ, Shi QL, Gong EY, et al. Multimorbidity guidelines: past, present and future[J]. Chinese Journal of Evidence-Based Medicine, 2024, 24(6): 621-625.]

30.Florisson S, Aagesen EK, Bertelsen AS, et al. Are older adults insufficiently included in clinical trials?-An umbrella review[J]. Basic Clin Pharmacol Toxicol, 2021, 128(2): 213-223.

31.Tinetti ME, Naik AD, Dodson JA. Moving from disease-centered to patient goals-directed care for patients with multiple chronic conditions: patient value-based care[J]. JAMA Cardiology, 2016, 1(1): 9-10.

32.Kuan V, Denaxas S, Patalay P, et al. Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study[J]. Lancet Digit Health, 2023, 5(1): e16-e27.

33.Weiss CO, Varadhan R, Puhan MA, et al. Multimorbidity and evidence generation[J]. J Gen Intern Med, 2014, 29(4): 653-660.

34.Lum DH, Choi MM, Cheung JOH, et al. Multimorbidity representation in randomized controlled trials of selective serotonin reuptake inhibitors: a systematic analysis of published trials[J]. J Affect Disord, 2023, 344: 261-266.

35.Fan J, Sun Z, Yu C, et al. Multimorbidity patterns and association with mortality in 0.5 million Chinese adults[J]. Chin Med J (Engl), 2022, 135(6): 648-657.

36.Tian Y, Li D, Cui H, et al. Epidemiology of multimorbidity associated with atherosclerotic cardiovascular disease in the United States, 1999-2018[J]. BMC Public Health, 2024, 24(1): 267.

37.Lima JP, Mirza RD, Guyatt GH. How to recognize a trustworthy clinical practice guideline[J]. J Anesth Analg Crit Care, 2023, 3(1): 9.

38.徐彩花, 周泳佳, 李艺羿, 等. 导航临床决策: 临床实践指南评价工具全景解析[J]. 中国循证医学杂志, 2025, 25(3): 367-372. [Xu CH, Zhou YJ, Li YY, et al. Navigating clinical decision making: panorama analysis of clinical practice guideline evaluation tools[J]. Chinese Journal of Evidence-Based Medicine, 2025, 25(3): 367-372.]

39.Brouwers MC, Kho ME, Browman GP, et al. Development of the AGREE II, part 1: performance, usefulness and areas for improvement[J]. CMAJ, 2010, 182(10): 1045-1052.

40.Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care: the right statement[J]. Ann Intern Med, 2017, 166(2): 128-132.

41.刁莎, 李思雨, 石雨晴, 等. 指南临床适用性评价工具(2.0版)解读[J]. 中国循证医学杂志, 2023, 23(11): 1318-1322. [Diao S, Li SY, Shi YQ, et al. Interpretation of the instrument for evaluating clinical applicability of guidelines (version 2.0)[J]. Chinese Journal of Evidence-Based Medicine, 2023, 23(11): 1318-1322.]

42.靳英辉, 赵志慧, 黄粲然, 等. 临床实践指南实施性评价工具的研制和验证评价[J]. 中国循证医学杂志, 2022, 22(1): 111-119. [Jin YH, Zhao ZH, Huang CR, et al. Development and validation for evaluation of an evaluation tool for guideline implementation[J]. Chinese Journal of Evidence-Based Medicine, 2022, 22(1): 111-119.]

43.Muth C, Van Den Akker M, Blom JW, et al. The Ariadne principles: how to handle multimorbidity in primary care consultations[J]. BMC Medicine, 2014, 12: 223.

44.Bakker L, Kemper PF, Wagner C, et al. A baseline assessment by healthcare professionals of Dutch pharmacotherapeutic care for the elderly with polypharmacy[J]. Eur J Public Health, 2017, 27(4): 679-686.

45.Alkubati SA, Al-Sayaghi KM, Alrubaiee GG, et al. Adherence of critical care nurses to endotracheal suctioning guidelines: a cross-sectional study[J]. BMC Nursing, 2022, 21(1): 312.

46.Ceška R, Štulc T. Implementation of cardiovascular disease prevention guidelines into clinical practice: an unmet challenge?[J]. Curr Pharm Des, 2015, 21(9): 1180-1184.

47.Latoszek-Berendsen A, Tange H, Van Den Herik HJ, et al. From clinical practice guidelines to computer-interpretable guidelines. A literature overview[J]. Methods Inf Med, 2010, 49(6): 550-570.

48.Alper BS. Making guidelines computable[J]. Clin Pub Health Guidelines, 2024, 1: e12014.

49.Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness[J]. JAMA, 2018, 320(9): 867-868.

50.廖茜雯, 姚晨, 张军, 等. 真实世界数据和证据在我国临床决策中的应用现状[J]. 中国食品药品监管, 2023, (10): 24-35. [Liao  XW, Yao C, Zhang J, et al. Application of real world data and evidence for clinical decision-making in China[J]. China Food and Drug Administration Journal, 2023, (10): 24-35.]

51.Canonica GW, Agache I, Schünemann HJ, et al. Next generation health guidelines: the role of real-life data in evidence-based medicine[J]. Allergy, 2024, 79(1): 12-14.

52.施秀青, 阎思宇, 黄桥, 等. 真实世界研究: 弥合临床实践指南与临床决策之间的距离[J]. 协和医学杂志, 2023, 14(4): 859-867. [Shi  XQ, Yan SY, Huang Q, et al. Real-world research: bridging the gap between clinical practice guidelines and clinical decision-making[J]. Journal of Peking Union Medical College Hospital, 2023, 14(4): 859-867.]

53.Subbiah V. The next generation of evidence-based medicine[J]. Nat Med, 2023, 29(1): 49-58.

54.Ford I, Norrie J. Pragmatic trials[J]. N Engl J Med, 2016, 375(5): 454-463.

55.Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available[J]. Am J Epidemiol, 2016, 183(8): 758-764.

56.Markle-Reid M, Mcainey C, Fisher K, et al. Effectiveness of a nurse-led hospital-to-home transitional care intervention for older adults with multimorbidity and depressive symptoms: a pragmatic randomized controlled trial[J]. PLoS One, 2021, 16(7): e0254573.

57.Usman MS, Pitt B, Butler J. Target trial emulations: bridging the gap between clinical trial and real-world data[J]. Eur J Heart Fail, 2021, 23(10): 1708-1711.

58.Kent DM, Steyerberg EW, Van Klaveren D. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects[J]. BMJ, 2018, 363: k4245.

59.An B. Construction and application of Chinese breast cancer knowledge graph based on multi-source heterogeneous data[J]. Math Biosci Eng, 2023, 20(4): 6776-6799.

60.Bhatia S, Richie R. Transformer networks of human conceptual knowledge[J]. Psychol Rev, 2024, 131(1): 271-306.

61.Jin YH, Ren XY, Yu LN, et al. Artificial intelligence for the development and implementation guidelines for traditional Chinese medicine and integrated traditional Chinese and western medicine[J]. TMR Modern Herbal Medicine, 2021, 4(2): 15-28.

62.Fux A, Soffer P, Peleg M. A layered computer-interpretable guideline model for easing the update of locally adapted clinical guidelines[J]. Health Informatics J, 2020, 26(1): 156-171.

63.Darzi AJ, Torabiardakani K, Bravo-Soto G, et al. Consolidation, systematic appraisal and comparison of guideline recommendations regarding management of chronic pain: protocol for a digital chronic pain recommendation map[J]. Clinical and Public Health Guidelines, 2025, 2(4): e70033.